As of 2023, 25% of self-funded plans included weight loss treatments, with expectations to rise to 43% in 2024, indicating a shifting landscape in coverage
These effects are generally mild and tend to diminish over time
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
Can GLP1 medications help my blood sugar and cholesterol, too
Employer-sponsored plans are increasingly adding obesity drug coverage, but adoption is uneven
What is included in your JourneyLite care Medication selection based on your medical profile Ongoing follow-up and dose adjustments Nutrition guidance and lifestyle coaching integrated into your plan Long-term strategy for maintenance and preventing regain Discussion of insurance coverage and practical alternatives when appropriate Safety, Eligibility, and Monitoring Prescription weight loss medication is medical care